Drug intelligence / Profile preview

UWD-19B

Development stage: Preclinical
Lead developer: Wondercel Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

UWD-19B is an allogeneic chimeric antigen receptor T-cell (CAR-T) therapy developed by Wondercel Therapeutics. It is engineered to dual-target B-cell maturation antigen (BCMA) and CD19, antigens commonly expressed on malignant plasma cells and B-cells. By utilizing an allogeneic ("off-the-shelf") approach, UWD-19B aims to provide a more accessible treatment option compared to patient-derived autologous therapies. The drug is currently in preclinical development for the treatment of multiple myeloma and various autoimmune diseases, where the depletion of pathogenic B-cells and plasma cells is a therapeutic goal.

Targets

CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on UWD-19B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UWD-19B.

Explore the full profile